Study analysis · Alzheimer's & Dementia : Translational Research & Clinical Interventions · 2025
What if a $5 supplement could boost your brain power — even with Alzheimer's?
People with Alzheimer's who took a daily scoop of creatine powder for two months saw their brain energy go up by 11% and got a little better at remembering and reading words.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study watched 20 people take a supplement and saw that their brains had more creatine and they did a little better on some memory tests. But because no one else took a fake pill for comparison, we don’t know if the supplement really caused the improvement or if it was just luck or practice.
What’s the bottom line?
Scientists gave older adults with Alzheimer's a daily powder called creatine for two months to see if it could help their brains use energy better.
How strong is this study?
This study didn’t use a control group or randomly assign people, so it’s like watching one person try a new video game and saying it’s the best ever — without checking if anyone else liked it more. That makes it hard to trust that the results are really because of the supplement.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
15 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control groupno control group
- Sample size (n=20)+1.9/20
- Follow-up+10/10
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervalsno confidence intervals
- Pre-registration+15/15
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 552 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design cannot establish causation — the findings describe an association, not a cause. This study has no control group, no randomization, and no blinding. It is a single-arm pre-post design, which cannot rule out placebo effects, practice effects, or other confounding factors that may explain observed changes.
Major COI
Major conflicts that significantly reduce study credibility
The study was funded by a company (Life Extension Inc.) that supplied the creatine monohydrate intervention, and while no direct author employment by the funder is stated, the funder's product was central to the trial, raising significant conflict concerns.
Funders
Conflict Details
Life Extension Inc.: Supplied the creatine monohydrate intervention used in the trial.
The study lacks a formal conflict of interest disclosure section and funding statement. The funder provided the intervention product but no details are given about whether they had any role beyond supply. The absence of independent oversight details and the direct link between the funder's product and study outcomes constitute a major conflict risk.
Key takeaways
- 01
19 out of 20 people took it correctly.
- 02
Their brain creatine went up by 11%.
- 03
They got slightly better at remembering things and reading words out loud.
- 04
These changes are small but meaningful — they suggest the brain might be getting more energy, which could help with thinking tasks like remembering or reading.
Surprising findings
- Creatine improved oral reading recognition more than memory tasks — even though Alzheimer's is known for memory loss.Most Alzheimer's treatments target memory, but this study found reading — a crystallized skill — improved the most. That suggests creatine may help preserved brain pathways, not just damaged ones.
- No decline in kidney or liver markers despite 20g/day — a dose 5x higher than typical athletic use.People fear creatine harms kidneys — but in Alzheimer's patients with potential organ vulnerability, no safety red flags emerged.
Practical takeaways
If you or a loved one has early Alzheimer's, talk to a doctor about trying 20g/day creatine monohydrate for 8 weeks — it's cheap, safe, and may help with reading and memory tasks.
This was a tiny, uncontrolled study. Don't expect dramatic results — improvements were modest, and long-term effects are unknown.
low confidenceWhy this study matters
95% Adherence in Alzheimer's Patients
Nineteen out of 20 participants with Alzheimer's took 20g of creatine daily for 8 weeks, achieving at least 80% compliance — even with memory challenges. No serious side effects occurred, and most mild issues like cramping faded within weeks.
This proves that even people with advanced cognitive decline can stick to a daily supplement routine — a huge win for non-drug interventions in dementia care.
Brain Creatine Jumped 11%
Using MRI spectroscopy, researchers found brain total creatine increased by 11% (p < .001) after 8 weeks of 20g/day creatine — the first time this has been shown in Alzheimer's patients.
Your brain needs energy to think — and creatine is like a battery charger for brain cells. This proves it actually reaches and boosts energy in Alzheimer's brains.
Reading & Memory Got Better
Participants improved significantly in oral reading recognition (p < .001) and working memory (list sorting, p = .001). Their ability to read words aloud got better — even if they couldn't remember names.
These aren't just lab numbers — they're real skills that help people connect with loved ones. Reading a card aloud or remembering a phone number matters deeply.
Creatine Reached the Brain — And It Showed Up in Blood
Serum creatine levels rose sharply (p < .001), and the increase correlated with brain creatine gains (r = 0.49, p = .004) — proving the supplement crosses the blood-brain barrier in Alzheimer's patients.
Many supplements fail to reach the brain. This one does — and we can measure it in the blood. That’s huge for future treatments.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists gave older adults with Alzheimer's a daily powder called creatine for two months to see if it could help their brains use energy better.
Research results
19 out of 20 people took it correctly. Their brain creatine went up by 11%. They got slightly better at remembering things and reading words out loud.
What this means - more context
These changes are small but meaningful — they suggest the brain might be getting more energy, which could help with thinking tasks like remembering or reading.
This study assessed the feasibility and preliminary effects of 20g/day creatine monohydrate supplementation for 8 weeks in adults with Alzheimer's disease.
In a single-arm pilot trial of 20 patients, creatine supplementation was well tolerated with 95% adherence, increased serum and brain creatine levels by 11%, and was associated with modest improvements in global and fluid cognition, including working memory and oral reading recognition. No serious adverse events occurred.
Methods Used
Twenty adults with Alzheimer's disease received 20g/day creatine monohydrate for 8 weeks in an uncontrolled, single-arm design. Compliance was tracked via logs and serum creatine levels. Brain total creatine was measured using 1H MRS, and cognition was assessed with NIH Toolbox and MMSE at baseline and 8 weeks.
Main Finding
Creatine supplementation increased brain total creatine by 11% (p < .001) and improved global cognition (p = .02) and fluid cognition (p = .004), with significant gains in oral reading recognition (p < .001) and list sorting (p = .001).
Confidence Level
Low — single-arm, no control group, small sample size (n=20), and pre-post design limit causal inference despite statistical significance and effect sizes.
Study Flags
Red Flags
- •No control group
- •Small sample size (n=20)
- •Single-arm pre-post design limits causal claims
Surprising Findings
Creatine improved oral reading recognition more than memory tasks — even though Alzheimer's is known for memory loss.
Most Alzheimer's treatments target memory, but this study found reading — a crystallized skill — improved the most. That suggests creatine may help preserved brain pathways, not just damaged ones.
Practical Takeaways
If you or a loved one has early Alzheimer's, talk to a doctor about trying 20g/day creatine monohydrate for 8 weeks — it's cheap, safe, and may help with reading and memory tasks.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 552 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
Moderate probability
on the GRADE evidence scale
This study watched 20 people take a supplement and saw that their brains had more creatine and they did a little better on some memory tests. But because no one else took a fake pill for comparison, we don’t know if the supplement really caused the improvement or if it was just luck or practice.
Major conflicts — industry funding with significant control over the research. Reporting score and overall score cap have been reduced.
Strengths
- Used objective biomarkers (serum creatine, MRS brain tCr) to support compliance and biological effect
- Used validated cognitive tools (NIH Toolbox, MMSE)
- Reported compliance and safety data transparently
Weaknesses
- No control group (no placebo or comparison condition)
- No randomization
- Blinding status unknown
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists gave older adults with Alzheimer's a daily powder called creatine for two months to see if it could help their brains use energy better.
Research results
19 out of 20 people took it correctly. Their brain creatine went up by 11%. They got slightly better at remembering things and reading words out loud.
What this means - more context
These changes are small but meaningful — they suggest the brain might be getting more energy, which could help with thinking tasks like remembering or reading.
This study assessed the feasibility and preliminary effects of 20g/day creatine monohydrate supplementation for 8 weeks in adults with Alzheimer's disease.
In a single-arm pilot trial of 20 patients, creatine supplementation was well tolerated with 95% adherence, increased serum and brain creatine levels by 11%, and was associated with modest improvements in global and fluid cognition, including working memory and oral reading recognition. No serious adverse events occurred.
Methods Used
Twenty adults with Alzheimer's disease received 20g/day creatine monohydrate for 8 weeks in an uncontrolled, single-arm design. Compliance was tracked via logs and serum creatine levels. Brain total creatine was measured using 1H MRS, and cognition was assessed with NIH Toolbox and MMSE at baseline and 8 weeks.
Main Finding
Creatine supplementation increased brain total creatine by 11% (p < .001) and improved global cognition (p = .02) and fluid cognition (p = .004), with significant gains in oral reading recognition (p < .001) and list sorting (p = .001).
Confidence Level
Low — single-arm, no control group, small sample size (n=20), and pre-post design limit causal inference despite statistical significance and effect sizes.
Study Flags
Red Flags
- •No control group
- •Small sample size (n=20)
- •Single-arm pre-post design limits causal claims
Surprising Findings
Creatine improved oral reading recognition more than memory tasks — even though Alzheimer's is known for memory loss.
Most Alzheimer's treatments target memory, but this study found reading — a crystallized skill — improved the most. That suggests creatine may help preserved brain pathways, not just damaged ones.
Practical Takeaways
If you or a loved one has early Alzheimer's, talk to a doctor about trying 20g/day creatine monohydrate for 8 weeks — it's cheap, safe, and may help with reading and memory tasks.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 552 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
Moderate probability
on the GRADE evidence scale
This study watched 20 people take a supplement and saw that their brains had more creatine and they did a little better on some memory tests. But because no one else took a fake pill for comparison, we don’t know if the supplement really caused the improvement or if it was just luck or practice.
Major conflicts — industry funding with significant control over the research. Reporting score and overall score cap have been reduced.
Strengths
- Used objective biomarkers (serum creatine, MRS brain tCr) to support compliance and biological effect
- Used validated cognitive tools (NIH Toolbox, MMSE)
- Reported compliance and safety data transparently
Weaknesses
- No control group (no placebo or comparison condition)
- No randomization
- Blinding status unknown
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
This study didn’t use a control group or randomly assign people, so it’s like watching one person try a new video game and saying it’s the best ever — without checking if anyone else liked it more. That makes it hard to trust that the results are really because of the supplement.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
15 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control groupno control group
- Sample size (n=20)+1.9/20
- Follow-up+10/10
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervalsno confidence intervals
- Pre-registration+15/15
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 552 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design cannot establish causation — the findings describe an association, not a cause. This study has no control group, no randomization, and no blinding. It is a single-arm pre-post design, which cannot rule out placebo effects, practice effects, or other confounding factors that may explain observed changes.
Major COI
Major conflicts that significantly reduce study credibility
The study was funded by a company (Life Extension Inc.) that supplied the creatine monohydrate intervention, and while no direct author employment by the funder is stated, the funder's product was central to the trial, raising significant conflict concerns.
Funders
Conflict Details
Life Extension Inc.: Supplied the creatine monohydrate intervention used in the trial.
The study lacks a formal conflict of interest disclosure section and funding statement. The funder provided the intervention product but no details are given about whether they had any role beyond supply. The absence of independent oversight details and the direct link between the funder's product and study outcomes constitute a major conflict risk.